二甲双胍分子机制的研究进展
发布时间:2018-09-05 09:39
【摘要】:二甲双胍是治疗T2DM的一线用药,其分子机制未明。主要通过轻度抑制线粒体呼吸链复合物Ⅰ,进而激动腺苷酸活化蛋白激酶(AMPK)来减少肝脏葡萄糖输出。除降糖外,二甲双胍在治疗多囊卵巢综合征(PCOS)、降低糖尿病微血管及大血管并发症方面均发挥作用,还可用于癌症的辅助治疗。
[Abstract]:Metformin is a first-line drug for the treatment of T2DM, and its molecular mechanism is unclear. Mild inhibition of mitochondrial respiratory chain complex 鈪,
本文编号:2223894
[Abstract]:Metformin is a first-line drug for the treatment of T2DM, and its molecular mechanism is unclear. Mild inhibition of mitochondrial respiratory chain complex 鈪,
本文编号:2223894
本文链接:https://www.wllwen.com/yixuelunwen/yiyaoxuelunwen/2223894.html
最近更新
教材专著